Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 09, 2025, titled "Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada".